Communiqués Adimmune Corporation

Actions

4142

TW0004142005

Produits pharmaceutiques

Cours en clôture Taiwan S.E. Autres places de cotation 05/08/2026			Varia. 5j.	Varia. 1 janv.
17,15 ^TWD	+1,48%		+2,39%	-9,50%

14/05	Adimmune Corporation publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
31/03	Adimmune Corporation publie ses résultats annuels pour l'exercice clos le 31 décembre 2025	CI

Communiqués

16/08/22	Adimmune : The Company is invited to the online institutional investor conference hosted by Cathay Securities Corporation	PU
12/08/22	Adimmune : announces financail statements of 2022 second quarter.	PU
09/08/22	Adimmune : To announce the completion status of execution of the stock repurchase	PU
27/07/22	Adimmune : Clarification of media reporting	PU
25/07/22	Adimmune : The Company is invited to the institutional investor conference hosted by First Securities Inc.	PU
29/06/22	Adimmune : Announcement of members of the Company's 3rd audit committee	PU
29/06/22	Adimmune : The Company's board of directors re-elected Dr. Chan Chi-Hsien as the chairperson	PU
29/06/22	Adimmune : Important resolutions of the Company's 2022 regular shareholders' meeting	PU
29/06/22	Adimmune : The list of the newly elected 21st directors (including independent directors) of the Company	PU
29/06/22	Adimmune : The Company's shareholders' meeting approved the release of non-compete restrictions on directors	PU
21/06/22	Adimmune : Clarification of media reporting	PU
09/06/22	Adimmune : Announcement of the board resolution to repurchase treasury shares	PU
29/03/22	Adimmune : Resolution by the board of directors not to distribute dividends.	PU
29/03/22	Subject:The Company's Board of Directors resolved to convene the 2022 Annual General Shareholders Meeting	PU
29/03/22	Adimmune : The board of directors approved the company's 2021 consolidated financial report.	PU
11/02/22	Subject:Announcement of the approval of the Company's quadrivalent influenza vaccine from China's National Medical Products Administration	PU
26/01/22	Adimmune : Change to the research and development officer of the company	PU
07/05/20	Taiwanese COVID-19 vaccine still has hurdles to clear: CECC expert	AQ
06/05/20	Adimmune : Taiwan's coronavirus vaccine proven effective on animal subjects	AQ
11/03/20	Adimmune : Taiwanese company looking to start Wuhan virus vaccine trials in May	AQ
10/05/17	Adimmune :'s Quadrivalent Flu Vaccine Approved by TFDA	PR
23/11/16	Adimmune : begins shipments to EU and Phase III trial in Europe	PR
21/10/16	Adimmune : Successfully Places NT$1.5 BN Guaranteed Convertible Bonds	PR